Lates News

On August 20, Novartis announced that its innovative product Nuralda (Arquerant hydrochloride tablets) has been approved by the National Medical Products Administration for the reduction of proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. It is reported that Nuralda is the first non-immunological therapy approved in China for the treatment of IgA nephropathy. It is also the first and currently the only highly selective endothelin A (ETA) receptor antagonist for this indication in the country.